DE60320599D1 - Pluripotenzdeterminierende Faktoren und deren Anwendung - Google Patents

Pluripotenzdeterminierende Faktoren und deren Anwendung

Info

Publication number
DE60320599D1
DE60320599D1 DE60320599T DE60320599T DE60320599D1 DE 60320599 D1 DE60320599 D1 DE 60320599D1 DE 60320599 T DE60320599 T DE 60320599T DE 60320599 T DE60320599 T DE 60320599T DE 60320599 D1 DE60320599 D1 DE 60320599D1
Authority
DE
Germany
Prior art keywords
pluripotency
maintain
factors
determining factors
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320599T
Other languages
English (en)
Other versions
DE60320599T2 (de
Inventor
Ian Chambers
Austin Gerard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of DE60320599D1 publication Critical patent/DE60320599D1/de
Application granted granted Critical
Publication of DE60320599T2 publication Critical patent/DE60320599T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
DE60320599T 2002-01-30 2003-01-30 Pluripotenzdeterminierende Faktoren und deren Anwendung Expired - Lifetime DE60320599T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0202149 2002-01-30
GBGB0202149.1A GB0202149D0 (en) 2002-01-30 2002-01-30 Pluripotency determining factors and uses thereof

Publications (2)

Publication Number Publication Date
DE60320599D1 true DE60320599D1 (de) 2008-06-05
DE60320599T2 DE60320599T2 (de) 2009-10-29

Family

ID=9930054

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60304037T Expired - Lifetime DE60304037T2 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierender faktor und deren anwendungen
DE60320599T Expired - Lifetime DE60320599T2 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierende Faktoren und deren Anwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60304037T Expired - Lifetime DE60304037T2 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierender faktor und deren anwendungen

Country Status (11)

Country Link
US (2) US7687266B2 (de)
EP (2) EP1698639B1 (de)
JP (1) JP2005536183A (de)
KR (1) KR20040093699A (de)
CN (1) CN1646562A (de)
AT (2) ATE393167T1 (de)
DE (2) DE60304037T2 (de)
DK (2) DK1470155T3 (de)
ES (1) ES2308616T3 (de)
GB (1) GB0202149D0 (de)
WO (1) WO2003064463A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067744A1 (ja) * 2003-01-31 2004-08-12 Sumitomo Pharmaceuticals Co., Ltd. 胚性幹細胞の自己複製決定因子
US20060288431A1 (en) * 2003-02-13 2006-12-21 Norio Nakatsuji Marker for undifferentiated state of cell and composition and method for separation and preparation of stem cells
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
WO2006025802A1 (en) * 2004-09-03 2006-03-09 Agency For Science, Technology And Research Method for maintaining pluripotency of stem/progenitor cells
US8192988B2 (en) * 2004-10-22 2012-06-05 University Of Central Florida Research Foundation, Inc. Methods for increasing potency of adult mesenchymal stem cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8759090B2 (en) * 2006-10-30 2014-06-24 University Of Central Florida Research Foundation, Inc. Stem cell banking system
GB0701062D0 (en) * 2007-01-19 2007-02-28 Evocell Ltd Biological materials and uses thereof
KR101516833B1 (ko) 2007-03-23 2015-05-07 위스콘신 얼럼나이 리서어치 화운데이션 체세포 재프로그래밍
EP2626416A3 (de) 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Umprogrammierung von somatischen Zellen
WO2009032456A2 (en) * 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
US9497943B2 (en) 2008-06-13 2016-11-22 Whitehead Institute For Biomedical Research Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides
CA2734128A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International, Inc. Methods for the production of ips cells
WO2011094538A1 (en) * 2010-01-29 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
KR20210134808A (ko) 2011-12-05 2021-11-10 팩터 바이오사이언스 인크. 세포를 형질감염시키는 방법들 및 생성물들
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
KR102121086B1 (ko) 2012-11-01 2020-06-09 팩터 바이오사이언스 인크. 세포에서 단백질을 발현시키는 방법들과 생성물들
CN103609526B (zh) * 2013-10-16 2015-10-07 中国科学院生物物理研究所 线粒体蛋白质翻译因子Guf1在雄性不育研究中的应用
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
JP2019528284A (ja) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4965796A (en) 1995-01-24 1996-08-14 Board Of Regents, The University Of Texas System Self-renewing pluripotent hematopoietic stem cell compositions, methods of use, and culture systems therefor
AU1802797A (en) 1996-02-16 1997-09-02 University Of Edinburgh, The Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2445611A1 (en) * 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy

Also Published As

Publication number Publication date
EP1698639B1 (de) 2008-04-23
WO2003064463B1 (en) 2004-02-12
ATE320446T1 (de) 2006-04-15
DE60304037T2 (de) 2006-11-09
EP1470155A2 (de) 2004-10-27
US7687266B2 (en) 2010-03-30
EP1470155B1 (de) 2006-03-15
CN1646562A (zh) 2005-07-27
ATE393167T1 (de) 2008-05-15
WO2003064463A3 (en) 2003-12-11
DK1470155T3 (da) 2006-07-24
GB0202149D0 (en) 2002-03-20
JP2005536183A (ja) 2005-12-02
KR20040093699A (ko) 2004-11-08
DK1698639T3 (da) 2008-07-14
US20050255573A1 (en) 2005-11-17
EP1698639A2 (de) 2006-09-06
EP1698639A3 (de) 2006-12-06
DE60320599T2 (de) 2009-10-29
US20100144039A1 (en) 2010-06-10
ES2308616T3 (es) 2008-12-01
DE60304037D1 (de) 2006-05-11
WO2003064463A2 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
DE60320599D1 (de) Pluripotenzdeterminierende Faktoren und deren Anwendung
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
ATE511753T1 (de) Postnatale stammzellen und deren verwendungen
ATE521658T1 (de) Silikon-polyetheramid-blockcopolymere
BR0308919A (pt) Células-tronco programáveis, desdiferenciadas de origem monocìtica, e sua produção e uso
MY162559A (en) Human anti-il-23 antibodies, compositions, methods and uses
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
NZ612132A (en) Immunomodulation using placental stem cells
BRPI0618486A2 (pt) uso de células progenitoras multipotentes em adultos
DE602005013422D1 (de) Formulierungen mit ceramiden und/oder pseudoceramiden und (alpha-)bisabolol zur behandlung von hautschäden
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
MY145117A (en) Disposable diaper
DE60210623D1 (de) Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen
ATE463282T1 (de) Zusammensetzung enthaltend lactobacillus oder bifidobacterium und deren verwendung
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
DK0774975T3 (da) Brug af stivelse til kinetiske transdermale anvendelser
BRPI0620291B8 (pt) método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
BRPI0605942A (pt) composição cosmética para o tratamento de fibras de queratina, dispositivo em aerossol, processo de tratamento cosmético, e, uso de uma composição cosmética
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
ATE363890T1 (de) Kationische polymerisate und deren verwendung in kosmetischen formulierungen
ATE340253T1 (de) Zellkonstrukte erhältlich aus mesenchymalen stammzellen und davon ableitbaren zellen und ihre verwendung
CY1110482T1 (el) Μεταλλαγμενο θηλαστικο εκτος του ανθρωπου για την εκφραση της υπομοναδας α6 του νικοτινικου υποδοχεα της ακετυλοχολινης και χρηση για τη διαλογη ουσιων ικανων να αλληλεπιδρουν με τον υποδοχεα αυτον
ATE530562T1 (de) Tlr3-glycosylierungsstandortmuteine und verwendungsverfahren dafür

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition